Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-30a-5p
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
PI3K/Akt
Cancer name
Non-Small Cell Lung Cancer
Cancer site
Lung
Treatment type
Chemotherapy
Drug
Gefitinib
Impact of wild-type ncRNA on chemotherapy resistance
Down
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
Combination therapy of gefitinib and mir-30a-5p may overcome acquired drug resistance through regulating the pi3k/akt pathway in non-small cell lung cancer.
Tissue resource
non-small cell lung cancer gefitinib-resistant cell lines NCI-H1650
non-small cell lung cancer gefitinib-resistant cell lines NCIH1975
non-small cell lung cancer gefitinib-resistant cell lines NCI-H460
Experiment
qRT-PCR,Western blot
Institute
Type Culture Collection of the Chinese Academy of Sciences
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.